The silent problem begins in the liver.

More than a quarter of the world's adults live with metabolic dysfunction–associated steatotic liver disease — and most have no idea. We're building LiverTwin™, an agentic-AI care pathway that finds clinically significant fibrosis (F2+) in routine clinical data, before damage becomes irreversible.